Chugai Pharmaceutical (OTCMKTS:CHGCY) Issues Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) issued its earnings results on Thursday. The company reported $0.25 earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%.

Chugai Pharmaceutical Stock Performance

Chugai Pharmaceutical stock traded down $0.07 on Friday, reaching $28.50. The company’s stock had a trading volume of 11,808 shares, compared to its average volume of 118,747. Chugai Pharmaceutical has a twelve month low of $19.50 and a twelve month high of $31.26. The business’s fifty day moving average price is $26.77 and its 200 day moving average price is $24.42. The company has a market cap of $93.79 billion, a price-to-earnings ratio of 35.63 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Separately, UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company has an average rating of “Strong Buy”.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.